H2Biologics focuses on developing innovative biotechnologies aimed at addressing critical needs in the healthcare sector. Their primary technology revolves around the creation of advanced biologics that leverage human-derived proteins and antibodies. This approach is designed to enhance therapeutic efficacy and safety, particularly in the treatment of various diseases. The company emphasizes the importance of utilizing human biology to create more effective and targeted treatments, which can lead to improved patient outcomes.

In addition to their biologics, H2Biologics is also engaged in the development of novel delivery systems that enhance the bioavailability and stability of their products. These systems are designed to ensure that therapeutic agents are delivered efficiently to the target sites within the body, maximizing their therapeutic potential. By integrating cutting-edge research with practical applications, H2Biologics aims to revolutionize the way biologics are developed and administered, ultimately contributing to advancements in personalized medicine and patient care.

United States

AbBC is a next generation ADC company that utilizes a biological conjugation process to target and deliver Granzyme B to cells for internalization and irreversible toxicity without the requirement of cleavage. Our pipeline of 7 fully human fusion proteins in ongoing preclinical development demonstrate inhibition and regression of tumor growth without toxicity. The platform enables the opportunity to methodically select ADC targets for development of new Granzyme B fusion proteins with major focus in oncology.

AbBC Therapies

Company Details